A Randomized, Non-Inferiority Study Comparing Efficacy and Safety of a Single Dose of Pegfilgrastim versus Daily Filgrastim in Pediatric Patients after Autologous Peripheral Blood Stem Cell Transplant

The EBMT activity survey: 1990–2010

(2012) J R Passweg et al.   BONE MARROW TRANSPLANTATION

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

(2012) C. Sebban et al.   EUROPEAN JOURNAL OF CANCER

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

(2011) C. Zwick et al.   ANNALS OF ONCOLOGY

Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide?

(2011) Panayiotis D. Ziakas et al.   CLINICAL TRANSPLANTATION

A Phase II study on the safety and efficacy of a single dose of pegfilgrastim for mobilization and transplantation of autologous hematopoietic stem cells in pediatric oncohematology patients

(2011) Simone Cesaro et al.   TRANSFUSION

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim

(2010) Panagiotis Samaras et al.   ANNALS OF HEMATOLOGY

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation

(2010) Aaron Gerds et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients

(2010) S Mathew et al.   BONE MARROW TRANSPLANTATION

Pegfilgrastim Appears Equivalent to Daily Dosing of Filgrastim to Treat Neutropenia After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma

(2010) Robert Rifkin et al.   Clinical Lymphoma Myeloma & Leukemia

Retrospective comparison of neutropenia in children with ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF

(2010) Emilie Milano-Bausset et al.   CLINICAL THERAPEUTICS

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Biosimilar agents in oncology/haematology: from approval to practice

(2010) Dietger Niederwieser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis

(2010) Felicetto Ferrara et al.   HEMATOLOGICAL ONCOLOGY

Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients

(2010) Sheri L. Spunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation

(2010) Panagiotis Samaras et al.   ONCOLOGY

Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support

(2009) L. Castagna et al.   ANNALS OF ONCOLOGY

Optimal use of G-CSF administration after hematopoietic SCT

(2009) M Trivedi et al.   BONE MARROW TRANSPLANTATION

Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors

(2009) Scott C. Borinstein et al.   PEDIATRIC BLOOD & CANCER

Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies

(2009) Peter Fritsch et al.   PEDIATRIC BLOOD & CANCER

Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy

(2008) S Dallorso et al.   BONE MARROW TRANSPLANTATION